2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines

被引：482

作者：

Ozer, H ^{[1
]}

Armitage, JO ^{[1
]}

Bennett, CL ^{[1
]}

Crawford, J ^{[1
]}

Demetri, GD ^{[1
]}

Pizzo, PA ^{[1
]}

Schiffer, CA ^{[1
]}

Smith, TJ ^{[1
]}

Somlo, G ^{[1
]}

Wade, JC ^{[1
]}

Wade, JL ^{[1
]}

Winn, RJ ^{[1
]}

Wozniak, AJ ^{[1
]}

Somerfield, MR ^{[1
]}

机构：

[1] Amer Soc Clin Oncol, Alexandria, VA 22314 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2000年 / 18卷 / 20期

关键词：

D O I：

10.1200/JCO.2000.18.20.3558

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：3558 / 3585

页数：28

共 164 条

[1] Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia [J].

Anaissie, EJ ;

Vartivarian, S ;

Bodey, GP ;

Legrand, C ;

Kantarjian, H ;

AbiSaid, D ;

Karl, C ;

VadhanRaj, S .

AMERICAN JOURNAL OF MEDICINE, 1996, 100 (01) :17-23

[2]

[Anonymous], 1994, J CLIN ONCOL, V12, P2471

[3] AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS [J].

ANTMAN, K ;

CROWLEY, J ;

BALCERZAK, SP ;

RIVKIN, SE ;

WEISS, GR ;

ELIAS, A ;

NATALE, RB ;

COOPER, RM ;

BARLOGIE, B ;

TRUMP, DL ;

DOROSHOW, JH ;

AISNER, J ;

PUGH, RP ;

WEISS, RB ;

COOPER, BA ;

CLAMOND, GH ;

BAKER, LH .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1276-1285

[4] Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial [J].

Bajorin, DF ;

McCaffrey, JA ;

Hilton, S ;

Mazumdar, M ;

Kelly, WK ;

Scher, HI ;

Spicer, J ;

Herr, H ;

Higgins, G .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2722-2727

[5] EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS [J].

BARLOGIE, B ;

SMITH, L ;

ALEXANIAN, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1353-1356

[6] Cost analyses of adjunct colony stimulating factors for acute leukemia: Can they improve clinical decision making [J].

Bennett, CL ;

Stinson, TJ ;

Laver, JH ;

Bishop, MR ;

Godwin, JE ;

Tallman, MS .

LEUKEMIA & LYMPHOMA, 2000, 37 (1-2) :65-70

[7] Use of hematopoietic colony-stimulating factors: The American Society of Clinical Oncology survey [J].

Bennett, CL ;

Smith, TJ ;

Weeks, JC ;

Bredt, AB ;

Feinglass, J ;

Fetting, JH ;

Hillner, BE ;

Somerfield, MR ;

Winn, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) :2511-2520

[8] Economic analyses of phase III cooperative cancer group clinical trials: Are they feasible? [J].

Bennett, CL ;

Golub, R ;

Waters, TM ;

Tallman, MS ;

Rowe, JM .

CANCER INVESTIGATION, 1997, 15 (03) :227-236

[9]

BENNETT DL, IN PRESS CANC INVEST

[10]

BENSINGER W, 1999, P AM SOC HEMATOL, V94, pA368

← 1 2 3 4 5 6 7 8 9 10 →